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Abstract —Current distance measurement techniques for pulse wave velocity (PWV) calculation are susceptible to intercenter 
variability. The aim of this study was to derive and validate a formula for this distance measurement. Based on carotid femoral 
distance in 1183 whole-body magnetic resonance angiograms, a formula was derived for calculating distance. This was 
compared with distance measurements in 128 whole-body magnetic resonance angiograms from a second study. The effects 
of recalculation of PWV using the new formula on association with risk factors, disease discrimination, and prediction of 
major adverse cardiovascular events were examined within 1242 participants from the multicenter SUMMIT study (Surrogate 
Markers of Micro- and Macrovascular Hard End-Points for Innovative Diabetes Tools) and 825 participants from the 
Caerphilly Prospective Study. The distance formula yielded a mean error of 7.8 mm (limits of agreement =−41.1 to 56.7 mm; 
P<0.001) compared with the second whole-body magnetic resonance angiogram group. Compared with an external distance 
measurement, the distance formula did not change associations between PWV and age, blood pressure, or creatinine (P<0.01) 
but did remove significant associations between PWV and body mass index (BMI). After accounting for differences in age, 
sex, and mean arterial pressure, intercenter differences in PWV persisted using the external distance measurement (F=4.6; 
P=0.004), whereas there was a loss of between center difference using the distance formula (F=1.4; P=0.24). PWV odds ratios 
for cardiovascular mortality remained the same using both the external distance measurement (1.14; 95% confidence interval, 
1.06–1.24; P=0.001) and the distance formula (1.17; 95% confidence interval, 1.08–1.28; P<0.001). A population-derived 
automatic distance calculation for PWV obtained from routinely collected clinical information is accurate and removes 
intercenter measurement variability without impacting the diagnostic utility of carotid–femoral PWV.  (Hypertension. 
2018;71:937-945. DOI: 10.1161/HYPERTENSIONAHA.117.10620.) • Online Data Supplement
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Arteriosclerosis is the stiffening of the arterial wall, which occurs with advancing age and is strongly associated 
with risk of future cardiovascular events.1 Carotid–femoral 
pulse wave velocity (PWV) is the current gold standard for 
the assessment of aortic stiffness and has been included in 
guidelines on blood pressure management and as an end point 
in randomized clinical trials.2,3
Calculation of PWV requires measurement of both a time 
interval between the arrival of pressure waves at the carotid and 
femoral arteries and the distance between the 2 measurement 
Pulse Wave Velocity Measurement
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sites. Despite the widespread use of PWV, there exists signifi-
cant discrepancies in how the distance is measured because of 
the necessity of estimating the distance traveled by the tortuous 
arteries within the body which cannot be appreciated or quan-
tified without imaging. Current recommendations advise for 
a direct distance to be used with a modifier of 0.8 based on a 
single study of 98 healthy volunteers who underwent magnetic 
resonance imaging (MRI).4,5 However, other studies of similar 
size using invasive measurements of PWV suggest a 2 measure-
ment subtraction technique as the most accurate.6 Even using the 
direct measurement technique, it is widely recognized that nor-
mal reference values vary from center to center, suggesting either 
a real difference in PWV between geographical communities of 
healthy adults or that intercenter technique variability exists.7
A need therefore exists to create a more reproducible tech-
nique for the assessment of distance for pulse wave calcula-
tion to aid in the discrimination between health and disease 
and to improve applicability of published reference ranges 
and cutoff values for consideration of elevated risk. Whole-
body magnetic resonance angiography (WB-MRA) allows the 
acquisition of the entire arterial tree in a single examination, 
allowing a direct arterial path length to be calculated. Using a 
suitably large data set, it is, thus, feasible that a formula for the 
calculation of path length based on routinely available met-
rics could be generated. The aim of this study was 4-fold: first 
to develop a formula for measuring arterial path length using 
only routine clinical data by training it against an MRI-based 
gold standard; second, to examine the performance of the 
formula in predicting the MRI-based path length in a valida-
tion data set; the third aim was to test whether use of this for-
mula in 2 separate data sets from the training data set reduces 
intercenter differences in the distribution of PWV measure-
ments from similar clinical groups; and finally, to test whether 
covariate associations with PWV using the new MRI learned 
path length formula differ from the associations using the 
current routinely used distance techniques in the 2 validation 
data sets. We hypothesized that a standardized formula for the 
assessment of path length would reduce intercenter variability 
without affecting the clinical application of the derived PWV.
Methods
Study Populations
Data from 3 study populations—the TASCFORCE study (Tayside 
Screening for Cardiovascular Events), the SUMMIT study (Surrogate 
Markers of Micro- and Macrovascular Hard End-Points for Innovative 
Diabetes Tools), and the CaPS (Caerphilly Prospective Study)—were 
used in the current study. The rationale, study design, techniques, 
and population demographics of each of these have been described 
in detail previously.8–10 These prior studies and the current study have 
been approved by an institutional review committee, with all sub-
jects providing written informed consent. The study was performed 
in adherence with the principles of the Declaration of Helsinki. The 
TASCFORCE data that support the findings of this study are available 
from the corresponding author on reasonable request. The SUMMIT 
data are available from H.M. Colhoun, A.C. Shore, L. Groop, and J. 
Nilsson on reasonable request. The CaPS data are available from Y. 
Ben-Shlomo on reasonable request.
The TASCFORCE study is a population study comprised of low 
to intermediate risk participants free from clinically apparent car-
diovascular disease who underwent WB-MRA from whom the path 
length formula was generated. The SUMMIT study is a multicenter 
European study examining markers of cardiovascular risk in a mixed 
population inclusive of those with and without diabetes mellitus 
and with and without established cardiovascular disease. All PWV 
measurements were performed using a SphygmoCor device, using a 
4-point distance technique using the suprasternal notch to umbilicus 
distance plus the umbilicus to the femoral distance minus the carotid 
to suprasternal notch distance, henceforth, referred to as PWVSUMM. 
One hundred fifty-eight SUMMIT study participants also underwent 
WB-MRA using the same technique as those in TASCFORCE as 
part of a related substudy.11 CaPS is a population-based cohort study 
which tried to recruit all men aged 45 to 59 years residing in the 
town of Caerphilly between 1979 and 1983. Some of these men un-
derwent PWV measurement at the fifth follow-up. In this populace, 
distance was measured using a 3-point technique measuring from 
the suprasternal notch to the femoral artery, minus the carotid to su-
prasternal notch distance, henceforth, referred to as PWVCaPS. In the 
SUMMIT substudy, the arterial path length formula generated from 
the TASCFORCE WB-MRA was compared against the same mea-
surements obtained using the same WB-MRA technique in a separate 
population. In the main SUMMIT study, the effects of the formula on 
intercenter PWV variability were examined as were its effects on the 
association between PWV and cardiovascular risk factors. CaPS data 
were used to examine if these effects are replicated in a population in 
whom PWV has been calculated using a different distance measure-
ment formula and its effects on the prognostic capability of PWV.
Path Length Formula
For the generation of the path length formula, the TASCFORCE 
study in which 1528 study participants underwent WB-MRA was 
used. The WB-MRA acquisition has been described in detail pre-
viously.12 To generate the path lengths, the 3D WB-MRA data sets 
were viewed offline (Carestream PACS Client Suite Version 10.1 sp1, 
Rochester, NY) by 1 of 4 image analysts. An arterial centerline was 
drawn between the bifurcation of the right common carotid artery 
and the right common femoral artery. From this a curved multiplanar 
reformat of the vessel was generated. The distance from the carotid 
bifurcation to the aortic arch was measured (proximal distance) and 
the distance from the aortic arch to the common femoral artery bifur-
cation (distal distance) was measured (see Figure 1). The distances 
were measured twice and an average of the 2 was used for subsequent 
analysis. For generation of the formula, the proximal distance was 
subtracted from the distal distance to represent the distance traveled 
by the pulse wave. Interobserver variability was assessed in 50 cases 
to ensure inter-reader consistency. The formula for the calculation of 
the distance was then generated using backward linear regression (see 
below for details of this). Although the left carotid–femoral distance 
was also measured and a formula generated, none of the clinical stud-
ies recorded side measured, and as the right side is recommended for 
measurement of PWV when possible,13 we have thus focused on this 
for the current study. The distance formula was used to recalculate 
PWV by using the formula distance divided by the carotid–femoral 
time interval produced by the SphygmoCor devices. For the remain-
der of the article, the PWV calculated using the WB-MRA derived 
formula distance shall be referred to as PWVMRA.
External Validation
One hundred forty-eight participants of the SUMMIT study under-
went WB-MRA using the same acquisition parameters and with the 
intra-arterial path length measured using the same technique as in 
the TASCFORCE cohort.14 This was then compared with the distance 
generated using the formula from the TASCFORCE cohort. PWV in 
this cohort was calculated using the 3 distances: the external distance 
(PWVSUMM), the true distance on MRI (PWVTD), and the formula dis-
tance (PWVMRA).
External Application
Using the formula, PWVMRA was calculated in both the SUMMIT and 
CaPS population. This was then compared with the PWVSUMM in the 
SUMMIT cohort for its effects on intercenter variability and the asso-
ciations between PWV and common risk factors and the PWVCaPS in 
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the CaPS population for its effects on the association between PWV 
and risk factors.
Statistical Analysis
Data are expressed as mean±SD for continuous variables, median 
(range) for ordinal variables, and N (%) for nominal variables. 
Normality tests with Shapiro–Wilk were undertaken. For derivation of 
a path length formula within the TASCFORCE population, the influ-
ence of clinical factors on carotid–femoral path length was quantified 
using linear regression modeling. Sex, age, height, weight, waist cir-
cumference, systolic blood pressure, diastolic blood pressure, heart 
rate, cholesterol, high-density lipoprotein, low-density lipoprotein, 
triglycerides, glucose, smoking status, smoking years, pack years, and 
BMI were the starting variables within the backward entry model. To 
avoid overfitting, the variables were initially split into 2 blocks and 
backward linear regression preformed. The variables remaining in the 
model at the end of the backward linear regression then inserted into 
a third backward linear regression performed  to generate the final 
distance formula. This formula was compared with the path length 
Figure 1. Demonstration of calculation 
of the right carotid femoral intra-arterial 
path length. Initially a whole-body 
magnetic resonance angiogram is 
produced (A), with a curved multiplanar 
reformat generated starting at the 
bifurcation of the right common carotid 
artery extending to the bifurcation of 
the right common femoral artery (B 
and C). The proximal distance from 
the common carotid bifurcation to the 
aorta is measured (B), with the common 
carotid to common femoral distance then 
measured (C). The path length is then 
calculated as C–2×B.
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measured on MRI in the SUMMIT substudy using Bland–Altman 
plots and 2-way mixed absolute agreement intraclass correlation coef-
ficient. Association between PWV and clinical variables was assessed 
using multiple linear regression with age, sex, and mean arterial pres-
sure (MAP) included as covariates in all regressions. Analysis of vari-
ance was used for the comparison of means when ≥3 groups were 
compared. Paired t tests were used to compare the PWV measure-
ments obtained using the derived formula and the original physical 
distance measurement. For comparing the PWV between centers, 
Analysis of covariance was run with PWV as an independent variable, 
study center as a fixed variable, and age, sex, and MAP as covariates. 
As only 2 of the 3 SUMMIT centers recruited those under the age of 
62 years and because of the known strong confounding effect of age, 
comparison between the 3 SUMMIT sites was limited to participants 
>62 years of age. The CaPS cohort only involved males ≥65 years, 
with a significantly lower prevalence of cardiovascular disease than 
SUMMIT. As all these factors are known to influence PWV consider-
ably, only males ≥65 years of age and free from cardiovascular disease 
were included in the analysis comparing the PWV in the 4 centers 
(Dundee, Exeter, Lund, and Caerphilly). Logistic regression analyses 
were undertaken to look at associations with cardiovascular outcomes. 
All data were analyzed using SPSS statistical package (version 21.0, 
IBM SPSS, Chicago, IL) and RStudio (The R Foundation, Version 
3.3.2). Significance was assumed when P<0.05.
Results
Study Populations
The demographics of the 3 different studies are described in 
Table 1.
Path Length Formula
The number of WB-MRA subjects available for analysis were 
1513. Of these, 240 were discarded as one of the readers for 
path length measurement provided significantly greater dis-
tances than the other 3 readers on the interobserver analy-
sis. Ninety additional data sets were discarded because of 
technical issues in creating the whole-body angiograms from 
the 4 separate angiography sequences. This left 1183 data sets 
for generation of the formula. On backwards linear regression, 
age, sex, heart rate, height, and weight were the strongest pre-
dictors of arterial path length, leaving the final formula for the 
calculation of the right sided distance being:
Right Carotid Femoral Path length
Age years= + × [ ]( )+100 36 0 70. . 137 81
0 51 0 18
.
. .
× [ ]( )
+ × [ ]( ) − × [
Height m
Weight kg heart rate bpm]( )
+ [ ] [ ]( )46 25 53 89. , . ,if female if male (1)
Left Carotid Femoral Path length
Age years= + × [ ]( ) +61 03 0 81 1. . 32 50
0 59 0 21
0 14
.
. .
.
× [ ]( )
+ × [ ]( ) + × [ ]( )
−
Height m
Weight kg DBP mm Hg
× [ ]( )
+ [ ] [ ]( )
heart rate bpm
if female if male60 51 68 48. , . .
 (2)
When applied within the TASCFORCE cohort, the for-
mula produced a mean path length of 444.7±20.5 mm with 
the true distance with a true path length of 446±35 mm. There 
was a slight overestimate with a mean difference of 1.97 mm 
(limits of agreement =−53.9 to 57.8 mm; P=0.02), intraclass 
correlation coefficient =0.51 (95% confidence interval [CI], 
0.47–0.55; P<0.001). There was some evidence of systematic 
bias, such that the formula overestimated short path lengths 
and underestimated long path lengths (see Figure 2A). Mean 
difference did not differ by age, but those over 70 years of age 
had wider variation between true distance and formula dis-
tance (Figure S1A in the online-only Data Supplement).
External Validation
Of the 148 SUMMIT WB-MRA data sets, a path length mea-
surement was possible in 128, with 20 lost because of techni-
cal issues combining the 4 angiogram stations into a single 
whole-body data set. Measured distance in the cohort was 
450±31 mm, compared with a formula distance of 458±22 
mm. Compared with the measured intra-arterial path length on 
the MRI, there was a small but significant overestimation of 
the path length distance by the formula with a mean difference 
of 7.8 mm (limits of agreement =−41.1 to 56.7 mm; P<0.001) 
and a moderate correlation between the 2 measures with an 
intraclass correlation coefficient of 0.55 (95% CI, 0.41–0.67; 
P<0.001); see Figure 2B. Mean difference did not differ by 
age, but those over 70 years of age had wider variation between 
true distance and formula distance (Figure S1B). Compared 
with the PWVTD (9.2±2.0 ms−1), PWVSUMM (11.0±2.6 ms−1) 
was significantly higher with a mean difference of 1.78 ms−1 
(limits of agreement =−0.56 to 4.12 ms−1; P<0.001), with a 
marked reduction in the magnitude of the difference and the 
variation when compared with PWVMRA (9.37±2.2 ms−1), with 
a mean difference of −0.17 ms−1, although this remained sta-
tistically significant (limits of agreement =−0.56 to 0.28 ms−1; 
P=0.002); see Figure 3.
Table 1. Characteristics of the 3 Study Cohorts
Characteristic TASCFORCE SUMMIT CaPS
N 1183 929 825
Age, y 54.1±8.3 68.4±8.5 72.3±3.9
Sex (male) 433 (37%) 606 (65.2%) 825 (100%)
Heart rate, bpm 63.3±10.0 59.6±10.5 67.9±13.0
Systolic BP, mm Hg 122.2±12.2 133.8±17.7 141.4±19.4
Diastolic BP, mm Hg 72.6±9.2 74.8±8.8 74.2±11.2
BMI, kg/m2 26.6±4.1 28.8±4.6 27.6±3.6
Current smoker, % 141 (12%) 76 (8%) 122 (15%)
Ex smoker, % 307 (26%) 480 (52%) 418 (51%)
Nonsmoker, % 729 (62%) 371 (40%) 285 (34%)
Hypertension 12 (1%) 590 (64%) 356 (43%)
Hypercholesterolemia 0 (0%) 622 (67%) 222 (27%)
CVD 0 (0%) 421 (45%) 119 (14%)
Diabetes mellitus 0 (0%) 568 (61%) 93 (11%)
Total cholesterol, mmol/L 5.47±0.97 4.34±1.05 4.85±1.02
BMI indicates body mass index; BP, blood pressure; CaPS, Caerphilly 
Prospective Study; CVD, cardiovascular disease; SUMMIT, Surrogate Markers of 
Micro- and Macrovascular Hard End-Points for Innovative Diabetes Tools; and 
TASCFORCE, Tayside Screening for Cardiovascular Events.
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External Application: SUMMIT
One thousand two hundred forty-two individuals underwent 
PWV measurement as part of the multicenter SUMMIT study. 
Three hundred forty-four individuals were excluded from 
analysis because of the center at which they were performed, 
not recording the distance and time components for PWV cal-
culation in their metadata. This left with 1025 individuals, of 
whom 96 were excluded because of missing ≥1 of the vari-
ables required by the formula for the calculation of path length 
distance, leaving 929 in the final analysis (Table 1). PWVSUMM 
in the cohort was 10.84±2.8 ms−1. When this was recalcu-
lated, there was a significantly lower PWVMRA of 9.94±2.5 
ms−1 (mean diff =0.90, SD=1.08, P<0.001). Compared with 
PWVSUMM, PWVMRA demonstrated similar correlations with 
age, MAP, and HbA1c, and a loss of correlation with BMI, 
cholesterol, and with only a weak relation remaining between 
PWVMRA and waist circumference and creatinine (see Table 3). 
Use of the distance formula did not weaken the difference in 
PWV between those with and those without cardiovascular dis-
ease (CVD), with significant differences observed using both 
the traditional PWVSUMM technique (CVD positive =11.2±3.0 
ms−1, CVD negative =10.5±2.5 ms−1, t =−3.6; P<0.001) and 
the PWVMRA technique (CVD positive =10.3±2.7 ms−1, CVD 
negative =9.6±2.3 ms−1, t=−4.1; P<0.001). When compar-
ing the PWV at the 3 European sites, there was a significant 
difference between all 3 using both PWVSUMM (F test =19.4; 
P<0.001) and PWVMRA (F test =17.4; P<0.001); however, 
there were differences in baseline variables between the 3 cen-
ters (see Table S1 for comparison of the baseline demograph-
ics between the 3 centers). After correcting for differences 
between centers in the distribution of important determinants 
of PWV—that is, age, sex, and MAP which are the strongest 
determinants for PWV—there remained a significant differ-
ence between sites for PWVSUMM (F test =24.4; P<0.001), 
whereas the difference using PWVMRA significantly reduced 
(F=5.0; P=0.007; see Table 2). Further corrections for BMI 
differences between centers did not result in any change in 
this outcome.
External Application: CaPS
Eight hundred twenty-five males underwent PWV assessment 
at visit V. PWV using the external distance measurement was 
11.6±2.9 ms−1. When this was recalculated, there was a signif-
icantly lower PWV of 10.7±2.7 ms−1 (mean difference =0.87, 
SD=0.93; P<0.001), although the magnitude of the difference 
was less pronounced than in the SUMMIT cohort. Association 
with age, MAP, and creatinine remained unchanged using 
either of the 2 distance techniques for PWV; however, the 
BMI showed a continued significant but inverse association 
with PWVMRA (see Table 3).
Figure 2. Bland–Altman and scatter plots of the predicted path length generated using the formula versus the true distance measured on 
whole body angiography in the TASCFORCE (A and B) and SUMMIT (C and D) cohorts. SUMMIT indicates Surrogate Markers of Micro- 
and Macrovascular Hard End-Points for Innovative Diabetes Tools; and TASCFORCE, Tayside Screening for Cardiovascular Events.
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At a median follow-up of 8.5 years (interquartile range, 
4.6–9.2 years), 154 (18.7%) participants had suffered a major 
adverse cardiovascular event, of which 79 (9.6%) were fatal. 
The age- and systolic blood pressure–adjusted odds ratio for 
PWVCaPS was 1.11 (95% CI, 1.04–1.18; P=0.003) per SD 
increase in PWVCaPS for major adverse cardiovascular events 
and 1.14 (95% CI, 1.06–1.24; P=0.001) for fatal cardiovascu-
lar events using multivariable logistic regression. These results 
were almost unchanged when the analysis was repeated using 
PWVMRA, with the age- and systolic blood pressure–adjusted 
odds ratio being 1.11 (95% CI, 1.03–1.20; P=0.004) per SD 
increase in PWVMRA for major adverse cardiovascular events 
and 1.17 (95% CI, 1.08–1.28; P<0.001) for fatal cardiovascu-
lar events.
Discussion
In the current study, we have developed a formula for the 
calculation of interarterial distance for PWV measurement 
and applied this in 2 independent study populations across 4 
European centers. Using this formula strengthens the asso-
ciation of PWV with traditional risk factors and removes dif-
ferences between centers but does not reduce discrimination 
between those with and without cardiovascular disease, nor 
does it reduce the prognostic strength of PWV.
Distance measurement inaccuracies are an inherent 
source of error in PWV calculation. Multiple studies have 
documented significant differences between carotid–femoral 
PWV and central aortic PWV,15,16 with this difference being 
markedly reduced when the true arterial path lengths are used 
in the carotid–femoral PWV calculation rather than the exter-
nal distance measurements.14,17 We are not the first to attempt 
to derive a formula for the calculation of the true arterial path 
length for use in PWV calculation. Weber et al6 produced a cal-
culation for distance being equal to the (height/4+7.28) from 
a population of 135 being investigated for coronary artery 
disease, but, however, used the distance from the ascending 
aorta to the aortic bifurcation as the comparator which is not 
representative of the path traveled by the pulse wave between 
the carotid and femoral artery. Filipovsky et al18 derived the 
calculation (height×0.29) in a population of 596 individuals 
predominantly free from cardiovascular disease but used an 
externally measured distance as the gold standard with all the 
aforementioned weaknesses this entails. Both techniques were 
examined by Huybrechts et al4 in a population of 98 healthy 
men and women, which found that the Weber calculation was 
accurate but less so than a direct distance with a modifier of 
0.8 and the Filipovsky calculation to be highly inaccurate. In 
our study, we found the distance formula to vary from the true 
distance by an average of 7.8±25 mm in an external validation 
cohort, which while having a minimally higher bias compared 
with the 2.6±38 mm reported for the direct distance×0.8 has 
far tighter limits of agreement. Although we observed signifi-
cant variation between the formula and true path length of all 
variations were up to 100 mm in a small number of individu-
als within both the derivation and the validation cohort, this is 
likely a consequence of anatomic variability of the vascular 
Figure 3. Bland–Altman plots comparing pulse wave velocity (PWV) calculated using the external distance (PWVSUMM), true distance 
on MRI (PWVTD), and formula distance (PWVMRA). A, PWVSUMM compared with PWVTD; B, PWVSUMM compared with PWVMRA; C, PWVMRA 
compared with PWVTD. MRA indicates magnetic resonance angiography; MRI, magnetic resonance imaging; SUMMIT, Surrogate Markers 
of Micro- and Macrovascular Hard End-Points for Innovative Diabetes Tools; and TD, true distance.
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tree rather than the formula, with differences in excess of 100 
mm also reported between external distance measurements 
and true path length in previous studies.4,6 There also exists 
further potential for greater variability in the real world using 
the direct distance×0.8 technique, where choice of measure-
ment device is also known to result in significantly different 
distances, with a sliding caliper producing shorter distances 
than tape measures, with this effect most pronounced in the 
obese.13,19–21
In the formula generated for the calculation of path length, 
we found height, weight, and heart rate to explain right carotid 
femoral path length. Although height and weight are well 
documented associates of body surface area and, therefore, 
vascular volume,22 it is not immediately apparent how heart 
rate would affect path length. One possibility is that as heart 
rate increases, stroke volume and, therefore, vascular disten-
sion falls, or alternately it may be that an increased heart rate 
reflects greater sympathetic activation with associated vas-
cular constriction.23 As a result, if all other variables were to 
remain equal but heart rate were to change, the formula dis-
tance would shift. Further work is therefore required to deter-
mine the effects of the formula on variability of measurement 
of longitudinal changes.
The strengths of the current technique are its use of read-
ily obtainable metrics, with age, height, and weight being 
almost ubiquitously collected in the routine clinical work-up 
of cardiovascular disease. Although the formula would be 
cumbersome if it had to be calculated by the clinician at the 
bedside, the calculation is far simpler than the multitude of 
calculations being undertaken by the devices used for PWV 
measurement currently, and if such an inbuilt calculation were 
to be demanded by the end point users, industry will almost 
certainly be quick to respond. By removing a further source of 
human error and variability, such a calculation will standard-
ize measurements across the globe, improving the applicabil-
ity of reference ranges and cutoff values used in guidelines for 
determining elevated risk.
In our study, as in previous work, we found a significant 
difference in PWV between centers even after accounting 
for age, sex, and MAP.7 In comparison, we found that using 
the formula generated in the TASCFORCE population, this 
difference was significantly reduced. Although this could be 
ascribed to regressing the PWVs of the study participants to a 
common mean, this would also reduce the association between 
risk factors and PWV and reduce the differences between 
those with and without disease. This was not the case in the 
Table 2. Comparison of PWV Across the 3 Sites Based on External Distance Measurement and Formula Distance 
Calculation in the SUMMIT Cohort and Between the 4 Sites When the CaPS Data Are Included
PWV 
Technique
SUMMIT CaPS  
Site 1 Site 2 Site 3 Site 4 Unadjusted Model 1 Model 2
N 279 194 262     
PWV
SUMM
11.4±2.5 12.1±2.9 10.5±2.3 F=19.4, P<0.001 F=24.4, P<0.001 F=23.4, P<0.001
PWV
MRA
11.1±2.4 10.4±2.3 9.9±2.5 F=17.4, P<0.001 F=5.0, P=0.007 F=5.0, P=0.007
N 110 33 70 705    
PWV
SUMM/CaPS
11.4±2.3 12.0±2.9 10.5±2.1 11.5±2.9 F=2.8, P=0.04 F=4.6, P=0.004 F=4.7, P=0.003
PWV
MRA
11.0±2.1 10.5±2.2 9.8±2.0 10.6±2.6 F=3.0, P=0.03 F=1.4, P=0.24 F=1.3, P=0.26
Model 1 corrected for sex, age, and mean arterial pressure. Model 2 adjusted for BMI in addition to the variables in Model 1. BMI indicates body 
mass index; CaPS, Caerphilly Prospective Study; MRA, magnetic resonance angiography; PWV, pulse wave velocity; SUMMIT, Surrogate Markers of 
Micro- and Macrovascular Hard End-Points for Innovative Diabetes Tools; and TD, true distance.
Table 3. Association of PWV Based on External Distance Measurement and Formula Distance Calculation in the SUMMIT and CaPS 
Cohort
Variable
SUMMIT CaPS
PWV
SUMM
PWV
MRA
PWV
CaPS
PWV
MRA
B (SE) P Value B (SE) P Value B (SE) P Value B (SE) P Value
Age, y 0.13 (0.009) <0.001 0.16 (0.008) <0.001 0.30 (0.02) <0.001 0.29 (0.02) <0.001
Mean arterial pressure, mm Hg 0.09 (0.007) <0.001 0.07 (0.006) <0.001 0.07 (0.007) <0.001 0.06 (0.007) <0.001
BMI, kg/m2 0.14 (0.02) <0.001 0.02 (0.01) 0.17 0.04 (0.03) 0.09 −0.06 (0.02) 0.008
Waist,* cm 0.05 (0.006) <0.001 0.01 (0.005) 0.003     
Total cholesterol, mmol/L −0.36 (0.08) <0.001 −0.12 (0.06) 0.054 −0.02 (0.09) 0.83 0.05 (0.08) 0.58
Creatinine, mg/mL 0.01 (0.004) 0.008 0.007 (0.003) 0.015 0.001 (0.002) 0.61 0.001 (0.002) 0.61
HbA1c, mmol/mol 0.05 (0.005) <0.001 0.02 (0.004) <0.001     
Glucose 0.001 (0.004) 0.13 0.00 (0.004) 0.99     
*Waist data not available in CaPS. BMI indicates body mass index; CaPS, Caerphilly Prospective Study; CaPS, Caerphilly Prospective Study; HbA1c, hemoglobin A1c; MRA, 
magnetic resonance angiography; PWV, pulse wave velocity; and SUMMIT, Surrogate Markers of Micro- and Macrovascular Hard End-Points for Innovative Diabetes Tools.
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current study with the only variables significantly impacted by 
the new formula being BMI and waist circumference—both 
of which are known to affect the accurate path length mea-
surement.14,20 We found no significant shift in the magnitude 
of differences in PWV between those with and those without 
cardiovascular disease and no substantial change in the hazard 
ratios for PWV for prediction of future major adverse cardio-
vascular events and mortality.
Despite the robustness of our population derivation and 
external validation in multiple centers using different tech-
niques, there remain some limitations within our study and 
a need for several avenues of further work. The formula was 
derived in a population of adults over 40 years of age and vali-
dated in populations with mean ages of 68 and 72 years; thus, 
the robustness of the distance formula in those under 40 years 
of age requires further study. All our centers were of European 
origin with 3 of the 5 populations examined being of pre-
dominantly white British descent, limiting conclusions to this 
populace. This is particularly pertinent given the reported dif-
ferences in the prevalence of the different anatomic variations 
in the branching patterns of the aortic arch between popula-
tions, which could introduce a consistent bias.24,25 However, 
because the most common variant is a bovine arch which 
would affect left-sided distances rather than right and other 
variations are much less common, the impact of this is likely 
to be small and would reinforce the current guidelines of using 
right-sided distances whenever technically feasible. For our 
external validation, we assumed the distance to have been 
measured on the right hand side as per current recommenda-
tions because this was not recorded in the final study data, 
which will not have been the case in all participants. However, 
this would have confounded the benefit of the formula, and 
thus, its impact would be to cause an apparent worsening of 
its accuracy and correlations potentially underestimating its 
true benefits. Although we have examined the effects of the 
formula on correlation with risk factors, on intercenter vari-
ability, and on prognosis, its effects on net reclassification of 
risk has yet to be examined. Finally, while we examined it in 
comparison to 2 external distance measurement techniques, 
both of these techniques used were multipoint subtraction 
techniques rather than the direct carotid–femoral distance 
with a modifier of 0.8.5
Perspectives
A population-derived automatic distance calculation for PWV 
obtained from routinely collected clinical information is accu-
rate and reduces measurement variability without impacting 
the diagnostic utility of carotid–femoral PWV. Uptake of this 
will lead to improved technique standardization and applica-
bility of guidelines and reference ranges.
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What Is New?
•	We describe a formula to calculate pulse wave velocity (PWV) path length 
based on routinely available clinical information derived from 1183 
whole-body magnetic resonance imagings.
•	This formula reduces intercenter differences in PWV while retaining as-
sociations with risk factors, presence of cardiovascular disease, and risk 
prediction.
What Is Relevant?
•	Reduction of intercenter differences in PWV calculation which are known 
to exist will improve applicability of reference ranges.
Summary
A population-derived automatic distance calculation for PWV ob-
tained from routinely collected clinical information is accurate and 
removes intercenter measurement variability without impacting the 
diagnostic utility of carotid–femoral PWV.
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Table S1: Comparison of baseline measures between the 3 SUMMIT sites in those ≥62 years 
old. 
Characteristic Site 1 Site 2 Site 3 P 
N 281 292 356  
Age (years) 73.8 ± 5.1 64.8 ± 8.2 67.1 ± 8.7 <0.001 
Sex (male) 202 124 196 0.01 
Heart rate (bpm) 57.4 ± 9.4 61.3 ± 11.9 59.9 ± 9.9 0.006 
Systolic BP (mmHg) 138.8 ± 18.1 134.6 ± 17.9 129.2 ± 16.0 <0.001 
Diastolic BP (mmHg) 74.4 ± 8.9 77.2 ± 8.9 73.1 ± 8.1 <0.001 
BMI (kg/m2) 27.7 ± 3.9 29.0 ± 4.3 28.5 ± 4.1 0.002 
Current smoker (%) 27 (10%) 23 (11%) 12 (4%) <0.001 
Ex smoker (%) 171 (61%) 106 (52%) 139 (51%) 
Non-smoker (%) 81 (29%) 76 (37%) 122 (45%) 
Hypertension 195 139 168 0.13 
Hypercholesterolaemia 183 146 191 0.28 
CVD 131 109 132 0.35 
Diabetes 174 115 173 0.25 
Total cholesterol (mmol/L) 4.40 ± 1.0 4.10 ± 0.97 4.35 ± 1.11 0.005 
LDL-Cholesterol (mmol/L) 2.56 ± 0.88 2.10 ± 0.84 2.30 ± 0.97 <0.001 
HDL-Cholesterol (mmol/L) 1.43 ± 0.46 1.27 ± 0.40 1.40 ± 0.40 <0.001 
Triglycerides (mmol/L) 1.37 ± 0.81 1.66 ± 0.88 1.41 ± 0.40 <0.001 
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Figure S1A: Box plot of difference between true distance and formula distance according to age 
decile in TASCFORCE (A) and SUMMIT (B) populations. 
 
  
 4 
Figure S1B: Box plot of difference between true distance and formula distance according to age 
decile in TASCFORCE (A) and SUMMIT (B) populations. 
 
